Dr Yi Chao Foong
@ycfoong.bsky.social
MS Neurologist & researcher | Lover of Tassie's wild places
Reposted by Dr Yi Chao Foong
We’re thrilled to see Dr Foong share his expertise on this global stage at #PACTRIMS. Over 50% of people with #MS are aged over 50, and his research is helping to shape their care. Dive into his team's latest papers here:
🔗 jnnp.bmj.com/content/earl...
🔗 journals.sagepub.com/doi/full/10....
🔗 jnnp.bmj.com/content/earl...
🔗 journals.sagepub.com/doi/full/10....
November 16, 2025 at 8:47 AM
We’re thrilled to see Dr Foong share his expertise on this global stage at #PACTRIMS. Over 50% of people with #MS are aged over 50, and his research is helping to shape their care. Dive into his team's latest papers here:
🔗 jnnp.bmj.com/content/earl...
🔗 journals.sagepub.com/doi/full/10....
🔗 jnnp.bmj.com/content/earl...
🔗 journals.sagepub.com/doi/full/10....
Reposted by Dr Yi Chao Foong
Can high-efficacy treatments improve outcomes for people diagnosed with #MultipleSclerosis later in life? Dr Yi Chao Foong @ycfoong.bsky.social from our #MSResearch Flagship explores this in his poster at #ECTRIMS2025
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
September 26, 2025 at 1:14 AM
Can high-efficacy treatments improve outcomes for people diagnosed with #MultipleSclerosis later in life? Dr Yi Chao Foong @ycfoong.bsky.social from our #MSResearch Flagship explores this in his poster at #ECTRIMS2025
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
Reposted by Dr Yi Chao Foong
Our MS Research Flagship's Prof Bruce Taylor is at #ECTRIMS2025! His poster explores how genetic oxidative stress and low Mediterranean diet intake combine to influence MS onset risk. More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
September 25, 2025 at 2:56 AM
Our MS Research Flagship's Prof Bruce Taylor is at #ECTRIMS2025! His poster explores how genetic oxidative stress and low Mediterranean diet intake combine to influence MS onset risk. More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
Reposted by Dr Yi Chao Foong
Our MS Research Flagship's Himanshu Saraswat is at #ECTRIMS2025! His study investigated whether rare genetic variants in families with multiple MS cases could help explain MS risk.
More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
September 25, 2025 at 3:06 AM
Our MS Research Flagship's Himanshu Saraswat is at #ECTRIMS2025! His study investigated whether rare genetic variants in families with multiple MS cases could help explain MS risk.
More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
More 👇
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
Reposted by Dr Yi Chao Foong
Dr Xin Lin from our MS Research Flagship is at #ECTRIMS2025! His poster reveals how genetic structural variation in complement component 4 affects risk of MS onset and disability progression.
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
September 25, 2025 at 3:01 AM
Dr Xin Lin from our MS Research Flagship is at #ECTRIMS2025! His poster reveals how genetic structural variation in complement component 4 affects risk of MS onset and disability progression.
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
🔗 msresearchflagship.org.au/researchers/ms-research-flagship-at-ectrims-2025
#MultipleSclerosis #MSResearch
Reposted by Dr Yi Chao Foong
Want to turbo charge your #science career with a #PhD? Find out if people living with #MS are ageing well in this project at @menzies-research.bsky.social
www.utas.edu.au/research/deg...
www.utas.edu.au/research/deg...
Available projects for research degrees | University of Tasmania - Are people living with MS ageing well?
Multiple sclerosis (MS) is the most common neurological disorder in yo...
www.utas.edu.au
August 24, 2025 at 11:52 PM
Want to turbo charge your #science career with a #PhD? Find out if people living with #MS are ageing well in this project at @menzies-research.bsky.social
www.utas.edu.au/research/deg...
www.utas.edu.au/research/deg...
Absolute pleasure to be part of this controversies in MS debate! Of course, real life practice sits in between the two positions, but much food for thought on both ends of the spectrum. #MS #multiplesclerosis #neurology journals.sagepub.com/doi/10.1177/...
Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? No - Yi Chao Foong, Helmut Butzkueven, 2025
journals.sagepub.com
June 22, 2025 at 7:08 AM
Absolute pleasure to be part of this controversies in MS debate! Of course, real life practice sits in between the two positions, but much food for thought on both ends of the spectrum. #MS #multiplesclerosis #neurology journals.sagepub.com/doi/10.1177/...
Reposted by Dr Yi Chao Foong
For people with existing autoimmune disorders who take immune checkpoint inhibitors, the risk of relapse appears to be much higher with myasthenia gravis (12 of 18 [67%], often severe) vs only 8 of 45 [18%] with multiple sclerosis. Why? pubmed.ncbi.nlm.nih.gov/40465294/
June 6, 2025 at 3:44 AM
For people with existing autoimmune disorders who take immune checkpoint inhibitors, the risk of relapse appears to be much higher with myasthenia gravis (12 of 18 [67%], often severe) vs only 8 of 45 [18%] with multiple sclerosis. Why? pubmed.ncbi.nlm.nih.gov/40465294/
🧠🌏 NEW PAPER: We surveyed Australian & New Zealand neurologists about climate change and brain health. Here's what we found 🧵
OA paper here: www.sciencedirect.com/science/arti...
OA paper here: www.sciencedirect.com/science/arti...
Climate change and neurology: A survey of neurologists in Australia and New Zealand
This study aimed to assess the perceptions of neurologists in Australia and New Zealand regarding climate change and its impact on neurological practi…
www.sciencedirect.com
April 7, 2025 at 2:49 AM
🧠🌏 NEW PAPER: We surveyed Australian & New Zealand neurologists about climate change and brain health. Here's what we found 🧵
OA paper here: www.sciencedirect.com/science/arti...
OA paper here: www.sciencedirect.com/science/arti...
Interesting study that shows trough NTZ levels affect JCV seroconversion, with low trough levels reducing risk of seroconversion #multiplesclerosis #MS jnnp.bmj.com/content/earl...
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis
Background Natalizumab is a highly effective drug for patients with relapsing-remitting multiple sclerosis (MS). A disadvantage of this treatment is the risk of progressive multifocal leukoencephalopa...
jnnp.bmj.com
March 31, 2025 at 11:19 PM
Interesting study that shows trough NTZ levels affect JCV seroconversion, with low trough levels reducing risk of seroconversion #multiplesclerosis #MS jnnp.bmj.com/content/earl...
New paper! How does cognition change over time in #MS? We analyzed longitudinal data using the iPad-based Processing speed test (PST). Full #OA paper here - onlinelibrary.wiley.com/doi/full/10....
Longitudinal Trajectories of Digital Cognitive Biomarkers for Multiple Sclerosis
Background Cognitive impairment is one of the most common and debilitating symptoms of relapsing–remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and...
onlinelibrary.wiley.com
March 4, 2025 at 3:40 AM
New paper! How does cognition change over time in #MS? We analyzed longitudinal data using the iPad-based Processing speed test (PST). Full #OA paper here - onlinelibrary.wiley.com/doi/full/10....
Chance for tasmanian RACP members to give feedback on the upcoming 20 year tassie preventative health strategy - www.racp.edu.au/policy-and-a... #RACP #politas #Tasmania
Member consultations
Four Column Grid with LinksFour Column Grid with Links
Get involved in RACP Policy and Advocacy and make a valuable contribution to the RACP, your profession, and the community
www.racp.edu.au
February 25, 2025 at 10:08 AM
Chance for tasmanian RACP members to give feedback on the upcoming 20 year tassie preventative health strategy - www.racp.edu.au/policy-and-a... #RACP #politas #Tasmania
Reposted by Dr Yi Chao Foong
Curious that this isn't bigger news -- Australia's most iconic multi-day walking track, rapidly being burnt out. This was 11:00 am yesterday, just south of Cradle Mountain: browser.dataspace.copernicus.eu?zoom=12&lat=...
February 11, 2025 at 10:33 AM
Curious that this isn't bigger news -- Australia's most iconic multi-day walking track, rapidly being burnt out. This was 11:00 am yesterday, just south of Cradle Mountain: browser.dataspace.copernicus.eu?zoom=12&lat=...
ANZ recommendations on MS management - congrats Jess, a comprehensive and contemporary look at optimal MS management! www.mja.com.au/journal/2025...
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 2
A safe, effective and comprehensive approach to managing MS is crucial for improving long term outcomes and quality of life in individuals affected by MS
www.mja.com.au
February 10, 2025 at 3:03 AM
ANZ recommendations on MS management - congrats Jess, a comprehensive and contemporary look at optimal MS management! www.mja.com.au/journal/2025...
yet another failed deescalation trial - not particularly surprising given fingolimod & natalizumab drove the results. #multiplesclerosis #neurology #MS pmc.ncbi.nlm.nih.gov/articles/PMC...
De‐Escalation of Disease‐Modifying Therapy in Multiple Sclerosis—A Danish Nationwide Cohort Study
High‐efficacy (HE) disease‐modifying therapies (DMT) are increasingly used to treat multiple sclerosis (MS). Concerns arise when considering the decreasing efficacy and increasing risk of adverse even...
pmc.ncbi.nlm.nih.gov
February 7, 2025 at 8:09 AM
yet another failed deescalation trial - not particularly surprising given fingolimod & natalizumab drove the results. #multiplesclerosis #neurology #MS pmc.ncbi.nlm.nih.gov/articles/PMC...
Reposted by Dr Yi Chao Foong
A randomized trial showed Factor XIa inhibitor (abelacimab) compared with the currently used Factor Xa blocking agents (rivoroxaban) for atrial fibrillation led to significantly less bleeding events, leading to early trial termination
nejm.org/doi/full/10....
nejm.org/doi/full/10....
January 22, 2025 at 10:11 PM
A randomized trial showed Factor XIa inhibitor (abelacimab) compared with the currently used Factor Xa blocking agents (rivoroxaban) for atrial fibrillation led to significantly less bleeding events, leading to early trial termination
nejm.org/doi/full/10....
nejm.org/doi/full/10....
ECTRIMS recommendations of AHSCT for MS and NMOSD: www.nature.com/articles/s41...
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT - Nature Reviews Neurolog...
Autologous haematopoietic stem cell transplantation (AHSCT) is a treatment option for some forms of multiple sclerosis (MS), but uncertainties remain about its implementation in clinical practice and ...
www.nature.com
January 23, 2025 at 12:19 AM
ECTRIMS recommendations of AHSCT for MS and NMOSD: www.nature.com/articles/s41...
🧠 New paper! How does upper limb function change over time in #MS? We analyzed longitudinal data using the iPad-based Manual Dexterity Test (MDT). Full #OA paper here: onlinelibrary.wiley.com/doi/10.1111/...
Longitudinal trajectories of digital upper limb biomarkers for multiple sclerosis
Background
Upper limb dysfunction is a common debilitating feature of relapsing-remitting multiple sclerosis (RRMS). We aimed to examine the longitudinal trajectory of the iPad®-based Manual Dexteri.....
onlinelibrary.wiley.com
December 24, 2024 at 2:45 AM
🧠 New paper! How does upper limb function change over time in #MS? We analyzed longitudinal data using the iPad-based Manual Dexterity Test (MDT). Full #OA paper here: onlinelibrary.wiley.com/doi/10.1111/...
DOT-MS: #MS DMT discontinuation trial - stopped early due to increased clinical/radiological relapse in discontinuation group (17.8%!!). On platform therapies with median age 55 and 5 years of disease stability jamanetwork.com/journals/jam...
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis
This randomized clinical trial investigates whether first-line disease-modifying therapy can be safely discontinued in patients with long-term stable multiple sclerosis.
jamanetwork.com
December 19, 2024 at 9:50 AM
DOT-MS: #MS DMT discontinuation trial - stopped early due to increased clinical/radiological relapse in discontinuation group (17.8%!!). On platform therapies with median age 55 and 5 years of disease stability jamanetwork.com/journals/jam...
Reposted by Dr Yi Chao Foong
I give this article an A+ just based on the title: "Sportizumab - Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial" www.sciencedirect.com/science/arti...
Sportizumab – Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial
Multiple Sclerosis (MS) represents a neuroinflammatory autoimmune disease characterized by the predominance of circulating T cell subsets with proinfl…
www.sciencedirect.com
December 17, 2024 at 5:56 AM
I give this article an A+ just based on the title: "Sportizumab - Multimodal progressive exercise over 10 weeks decreases Th17 frequency and CD49d expression on CD8+ T cells in relapsing-remitting multiple sclerosis: A randomized controlled trial" www.sciencedirect.com/science/arti...
New paper! 📜 Happy to share our paper on #COVID infection on #MS disease activity using MSBase data! COVID was linked to a higher relapse rate and shorter time to first relapse. #multiplesclerosis
#OA paper here: tinyurl.com/ymn3fp6k
#OA paper here: tinyurl.com/ymn3fp6k
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
tinyurl.com
December 11, 2024 at 12:28 AM
New paper! 📜 Happy to share our paper on #COVID infection on #MS disease activity using MSBase data! COVID was linked to a higher relapse rate and shorter time to first relapse. #multiplesclerosis
#OA paper here: tinyurl.com/ymn3fp6k
#OA paper here: tinyurl.com/ymn3fp6k
Reposted by Dr Yi Chao Foong
Yes, I really want you to get your COVID19 vaccine. pubmed.ncbi.nlm.nih.gov/39525878/
The impact of COVID-19 infection on multiple sclerosis disease course across 12 countries: a propensity-score-matched cohort study - PubMed
COVID-19 infection was associated with a significantly increased MS relapse rate and a shorter time to first relapse. There was no effect on confirmed EDSS progression over the short term. These resul...
pubmed.ncbi.nlm.nih.gov
December 7, 2024 at 5:43 PM
Yes, I really want you to get your COVID19 vaccine. pubmed.ncbi.nlm.nih.gov/39525878/